This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Shigella Vaccine (Immuron)
Drug Names(s): Shigella vaccine
This is a Shigella specific bovine immunoglobulin product utilizing Immunron's oral immunotherapy platform and antigens identified by the Walter Reed Army Institute of Research. Polyclonal antibodies are produced by vaccinating pregnant cows with specific antigens and harvesting colostrum upon calving. The products are suitable for oral administration and are not destroyed in the stomach.
Compared with normal cow’s milk, bovine colostrum contains increased concentrations of immunoglobulins (mainly IgG) and other physically protective milk proteins. IgGs are not absorbed into the blood and act in the lumen against bacterial antigens. Polyclonal antibodies have the ability to target antigens in a less specific manner which improves their efficacy in the case of mutating bacteria.
Deal Structure: Immuron is developing the Shigella vaccine with the Walter Reed Army Institute of Research (WRAIR).
Shigella Vaccine (Immuron) News
Pink Sheet FDA Performance Tracker: CBER Approvals
Additional information available to subscribers only: